Search results for "Diabetes"
MKSAP Quiz: Evaluation for a carotid bruit
A 67-year-old man is evaluated for a carotid bruit detected on routine medical examination. He reports no history of previous focal neurologic symptoms or visual loss. He has type 2 diabetes mellitus and hyperlipidemia treated with metformin, moderate-intensity pravastatin, and aspirin. Following a physical exam, neurological exam, and lab results, what is the most appropriate next step in management?
https://acpinternist.org/weekly/archives/2019/11/12/3.htm
12 Nov 2019
Diabetes debates defy easy resolution
An ever-changing knowledge base without clear consensus makes diabetes management especially challenging.
https://acpinternist.org/archives/2013/09/diabetes.htm
1 Sep 2013
Studies of LDL levels, therapies support treatment of those older than age 70
A retrospective study found the association between low-density lipoprotein (LDL) cholesterol levels and cardiovascular events to increase with age, while a meta-analysis highlighted the benefits of statins and other lipid-lowering therapies in older patients.
https://acpinternist.org/weekly/archives/2020/11/17/4.htm
17 Nov 2020
MKSAP quiz: Evaluation during a routine examination
A 59-year-old man is evaluated during a routine examination. He feels well and has no symptoms. Medical history is significant for hypertension. On physical examination, the patient is afebrile, blood pressure is 122/74 mm Hg, and pulse rate is 76/min. Cardiac examination is unremarkable. What is the most appropriate next step in management?
https://acpinternist.org/weekly/archives/2019/12/17/3.htm
17 Dec 2019
GLP-1 receptor agonists may offer kidney protection in patients with type 2 diabetes
An industry-conducted pooled analysis of two large trials of glucagon-like peptide-1 (GLP-1) receptor agonists found that both semaglutide and liraglutide slowed kidney function decline, with semaglutide appearing to have the greatest effect.
https://acpinternist.org/weekly/archives/2021/12/21/2.htm
21 Dec 2021
New drugs approved for type 2 diabetes and COPD
This regulatory update covers dapaglifozin (Farxiga) a sodium-glucose co-transporter 2 inhibitor, to treat diabetes, and umeclidinium and vilanterol inhalation (Anoro Ellipta) for maintenance of chronic obstructive pulmonary disease.
https://acpinternist.org/archives/2014/03/fda.htm
1 Mar 2014
Diabetes meeting features research on prevention, drug effects, complications
CHICAGO—Long-term effects of lifestyle modification and hospitalization rates for complications of diabetes and diabetes treatment were among the research findings presented at the American Diabetes Association's Scientific Sessions last week.
https://acpinternist.org/weekly/archives/2013/07/02/1.htm
2 Jul 2013
MKSAP Quiz: 3-year history of severe rheumatoid arthritis
A 67-year-old woman is evaluated for a 3-year history of severe rheumatoid arthritis. After some changes in therapy, she has done well with tocilizumab and methotrexate over the past year. She notes several months of prominent fatigue. Lab studies demonstrate anemia. What is its most likely cause?
https://acpinternist.org/weekly/archives/2020/09/01/5.htm
1 Sep 2020
Kidney failure, CV events lower with canagliflozin than placebo, industry study finds
The trial was stopped early after an interim safety analysis found significantly better renal and cardiovascular outcomes among type 2 diabetes patients randomized to canagliflozin than those assigned to placebo.
https://acpinternist.org/weekly/archives/2019/04/23/2.htm
23 Apr 2019
Disorder or disease? Semantics of obesity
A reader questions the best way to talk about weight.
https://acpinternist.org/archives/2021/10/letter.htm
1 Oct 2021